Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Lifetime Brain Metastasis Risk in Older Patients With Cancer

Older adults with lung, breast, and skin cancers have an increased risk of developing brain metastasis during their lifetime. But how big is this risk? In an effort to find out, researchers used data from the Surveillance, Epidemiology, and End Results (SEER) Program on patients with lung cancer, breast cancer, or melanoma diagnosed with a brain metastasis, either one identified during primary cancer staging workup, called a synchronous brain metastasis (SBM), or one detected later in life, call...
Continue reading

New Therapeutic Target for Melanoma Brain Metastases

Almost half of patients with malignant melanoma develop metastases in different organs, with 60% of metastases spreading to the brain. Once the cancer metastasizes, the 5-year survival rate plummets to 5% to 19%. Metastasized malignancies are resistant to current immunotherapies and targeted therapies; however, researchers at the University of Texas MD Anderson Cancer Center discovered that oxidative phosphorylation (OXPHOS) can be a potential treatment target."Brain metastases are increasingly ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.